TORONTO, Nov. 11, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) announces today that their European distribution partner MedVec, in cooperation with partner company Ulti Med Products (Deutschland) GmbH, will showcase Biosign solutions, including the UFIT® TEN-10 Blood Pressure monitor and cardiovascular health software at MEDICA in Dusseldorf Germany, November 16-19 in Hall 3, Booth 41.
"Cardiovascular disease (CVD) is the leading cause of death in Germany with more than 400,000 fatalities a year linked directly to CVD. The German social health system spends over €40 billion (about $60 billion U.S.) each year on CVD," said MedVec Founder & CEO Mr. Knut Butzinger. "Biosign offers patients, caregivers and payers accurate cardiovascular health data that will improve quality of care and reduce costs associated with CVD. The UFIT health monitor could provide warning alerts that would flag 'at risk' patients for early interventions, reducing costs associated with emergency care. We are very excited about offering Biosign's technology to the state agencies and organizations we work with."
MedVec International is headquartered in Neckargemünd, Germany (near Heidelberg) and specializes in marketing, sales and distribution of innovative diagnostic technologies covering women's health, family health and diabetes to Germany, France, Austria and several other European countries. The German Pharmacists Association (BDA) recently awarded the MedVec "Yes or No" early detection pregnancy test "Medical Product of the Year 2011."
"Cardiovascular disease screening and monitoring could turn the tide on CVD medical costs in Germany," said Dr. Scott Jenkins, Biosign CEO. "Partnerships with best in class providers like MedVec allow us to work closely with German healthcare organizations and provide customized solutions that meet specific localized needs."
MEDICA is considered the premier Global Medical Industry trade show and exhibition which regularly features 4,400 exhibitors. MEDICA is known to have up to 138,000 participants from over 100 countries looking at the current and potential future trends for patient care.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, life style and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information, please visit www.biosign.com.
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators www.sedar.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.